Compare KBH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | CELC |
|---|---|---|
| Founded | 1957 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | KBH | CELC |
|---|---|---|
| Price | $51.96 | $120.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $56.17 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 1.3M | 643.5K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $4,547,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.60 | $740.70 |
| P/E Ratio | $99.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.17 | $9.50 |
| 52 Week High | $68.71 | $125.00 |
| Indicator | KBH | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 57.58 |
| Support Level | $48.89 | $99.38 |
| Resistance Level | $66.32 | N/A |
| Average True Range (ATR) | 1.68 | 6.11 |
| MACD | 0.43 | 0.91 |
| Stochastic Oscillator | 69.98 | 77.26 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.